NGM Biopharmaceuticals, Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

NGM Biopharmaceuticals, Inc. added its name to a long and growing list of biopharmaceutical companies raising $100m-plus venture capital mega-rounds with a $122m series A round announced on 17 July.

Kronos Bio, Inc. implemented a restructuring plan in November that resulted in a 19% workforce reduction but extended its cash runway into 2026 and the company unveiled further cost cuts on 7 March t